Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Gliclazide 80mg tablets
0601021M0AAAAAA
|
Gliclazide | Gliclazide | Endocrine System | 389,504 |
|
Gliclazide 40mg tablets
0601021M0AAARAR
|
Gliclazide | Gliclazide | Endocrine System | 235,741 |
|
Gliclazide 30mg modified-release tablets
0601021M0AAAMAM
|
Gliclazide | Gliclazide | Endocrine System | 84,055 |
|
Gliclazide 60mg modified-release tablets
0601021M0AAATAT
|
Gliclazide | Gliclazide | Endocrine System | 29,158 |
|
Gliclazide 160mg tablets
0601021M0AAAVAV
|
Gliclazide | Gliclazide | Endocrine System | 9,790 |
|
Gliclazide 80mg/5ml oral suspension
0601021M0AAASAS
|
Gliclazide | Gliclazide | Endocrine System | 307 |
|
Gliclazide 40mg/5ml oral suspension
0601021M0AAAUAU
|
Gliclazide | Gliclazide | Endocrine System | 171 |
|
Gliclazide 100mg/5ml oral suspension
0601021M0AAALAL
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 120mg/5ml oral suspension
0601021M0AAAIAI
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 160mg/5ml oral suspension
0601021M0AAAJAJ
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 20mg/5ml oral suspension
0601021M0AAANAN
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 30mg/5ml oral suspension
0601021M0AAAPAP
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 50mg/5ml oral suspension
0601021M0AAAHAH
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 60mg/5ml oral suspension
0601021M0AAAGAG
|
Gliclazide | Gliclazide | Endocrine System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.